Lumobiotics GmbH

Lumobiotics develops light-controllable peptide drugs as safe cytolytic agents for treatment of solid cancers and localized infectious diseases. We are dedicated to fostering the development of chemotherapeutics based on the technology platform, utilizing molecular photoswitches. Our drug candidates are peptidic therapeutics, modified by photoisomerizable building blocks. They can toggle between two forms, inactive and active, upon irradiation with light of different wavelength. The inactive (and non-toxic) photoswitchable peptidic drugs are administered to the patients. Switching the biological activity “on” with non-thermal red light irradiation in the sites of lesions (tumors, wounds) allows avoiding side-effects in the healthy tissues. Current target indications: bladder cancers, hepatocellular carcinoma, implant infections.